Home › Companies › CUE BIOPHARMA INC. › 2023-2024
At CUE BIOPHARMA INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 90 asset managers reported how they voted on 8 ballot items in their SEC Form N-PX filings, covering 754 separate fund positions. On the most widely held item on that ballot — The approval, on a non-binding advisory basis, of the compensation of our named executive… — CUE BIOPHARMA INC.'s filing reports the proposal as approved, with 86% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CUE BIOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CUE BIOPHARMA INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2024: 8 items on CUE BIOPHARMA INC.’s Form 8-K, filed June 7, 2024: 6 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore CUE BIOPHARMA INC. in the interactive database Compare manager voting policies
These tallies are CUE BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Daniel R. Passeri | 13,099,740 | -- | -- | 765,119 | 20,311,373 | 94% | Elected | — |
| Elect Director: Frank Morich | 7,990,004 | -- | -- | 5,605,204 | 20,581,024 | 59% | Elected | — |
| Elect Director: Frederick Driscoll | 12,486,167 | -- | -- | 1,378,692 | 20,311,373 | 90% | Elected | — |
| Elect Director: Pamela Garzone | 13,169,810 | -- | -- | 695,049 | 20,311,373 | 95% | Elected | — |
| Elect Director: Peter A. Kiener | 9,038,525 | -- | -- | 4,822,811 | 20,314,896 | 65% | Elected | — |
| Elect Director: Patrick Verheyen | 13,138,525 | -- | -- | 726,334 | 20,311,373 | 95% | Elected | — |
| 2. The appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, with votes cast | 32,418,349 | 1,635,231 | 122,652 | -- | -- | 95% | Approved | — |
| 3. Non-binding advisory proposal on the compensation of the Company's named executive officers, with votes cast | 11,745,009 | 1,924,707 | 195,143 | -- | 20,311,373 | 86% | Approved | — |
Source: CUE BIOPHARMA INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
Each item below shows how the 90 asset managers that disclosed a CUE BIOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of six directors to our board of directors, each to serve until the 2025 annual meeting of stockholders: Daniel R. Passeri
CUE BIOPHARMA INC.’s own tally for this item (“Elect Director: Daniel R. Passeri”): 13,099,740 for, 765,119 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following nominees to the Company's Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 31 asset managers below reported 2,428,070 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 61,732 | 0 | 0 | 0 | For |
| Dimensional | 56,839 | 0 | 0 | 0 | For |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,743 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 28,405 | 0 | 0 | 0 | For |
| Northern Trust | 16,002 | 0 | 0 | 0 | For |
| Voya | 13,439 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 11,159 | 0 | 0 | 0 | For |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 8,875 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 5,870 | 0 | 0 | 0 | For |
| Victory Capital | 5,748 | 0 | 0 | 0 | For |
| John Hancock | 5,565 | 0 | 0 | 0 | For |
| DWS | 5,402 | 0 | 0 | 0 | For |
| Jackson National | 5,401 | 0 | 0 | 0 | For |
| Principal | 4,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 4,042 | 0 | 0 | 0 | For |
| Calvert | 2,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
59% Majority: yes · of votes cast
Description as filed by funds: Election of six directors to our board of directors, each to serve until the 2025 annual meeting of stockholders: Frank Morich
CUE BIOPHARMA INC.’s own tally for this item (“Elect Director: Frank Morich”): 7,990,004 for, 5,605,204 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following nominees to the Company's Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:”
Support: 59% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 31 asset managers below reported 2,068,576 for, 359,494 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 91,531 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 61,732 | Withhold |
| Dimensional | 0 | 0 | 0 | 56,839 | Withhold |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 31,743 | Withhold |
| Managed Portfolio Series | 0 | 0 | 0 | 28,405 | Withhold |
| Northern Trust | 0 | 0 | 0 | 16,002 | Withhold |
| Voya | 0 | 0 | 0 | 13,439 | Withhold |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 5,959 | 0 | 0 | 5,200 | Mixed |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 8,875 | Withhold |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 5,870 | Withhold |
| Victory Capital | 0 | 0 | 0 | 5,748 | Withhold |
| John Hancock | 0 | 0 | 0 | 5,565 | Withhold |
| DWS | 0 | 0 | 0 | 5,402 | Withhold |
| Jackson National | 0 | 0 | 0 | 5,401 | Withhold |
| Principal | 0 | 0 | 0 | 4,525 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 4,042 | Withhold |
| Calvert | 0 | 0 | 0 | 2,854 | Withhold |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: Election of six directors to our board of directors, each to serve until the 2025 annual meeting of stockholders: Frederick Driscoll
CUE BIOPHARMA INC.’s own tally for this item (“Elect Director: Frederick Driscoll”): 12,486,167 for, 1,378,692 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following nominees to the Company's Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 31 asset managers below reported 2,299,501 for, 128,569 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 61,732 | Withhold |
| Dimensional | 0 | 0 | 0 | 56,839 | Withhold |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,000 | 0 | 0 | 1,743 | Mixed |
| Managed Portfolio Series | 28,405 | 0 | 0 | 0 | For |
| Northern Trust | 16,002 | 0 | 0 | 0 | For |
| Voya | 13,439 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 11,159 | 0 | 0 | 0 | For |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 8,875 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 5,870 | 0 | 0 | 0 | For |
| Victory Capital | 5,748 | 0 | 0 | 0 | For |
| John Hancock | 5,565 | 0 | 0 | 0 | For |
| DWS | 5,402 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 5,401 | Withhold |
| Principal | 4,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 4,042 | 0 | 0 | 0 | For |
| Calvert | 0 | 0 | 0 | 2,854 | Withhold |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of six directors to our board of directors, each to serve until the 2025 annual meeting of stockholders: Pamela Garzone
CUE BIOPHARMA INC.’s own tally for this item (“Elect Director: Pamela Garzone”): 13,169,810 for, 695,049 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following nominees to the Company's Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 31 asset managers below reported 2,428,070 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 61,732 | 0 | 0 | 0 | For |
| Dimensional | 56,839 | 0 | 0 | 0 | For |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,743 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 28,405 | 0 | 0 | 0 | For |
| Northern Trust | 16,002 | 0 | 0 | 0 | For |
| Voya | 13,439 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 11,159 | 0 | 0 | 0 | For |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 8,875 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 5,870 | 0 | 0 | 0 | For |
| Victory Capital | 5,748 | 0 | 0 | 0 | For |
| John Hancock | 5,565 | 0 | 0 | 0 | For |
| DWS | 5,402 | 0 | 0 | 0 | For |
| Jackson National | 5,401 | 0 | 0 | 0 | For |
| Principal | 4,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 4,042 | 0 | 0 | 0 | For |
| Calvert | 2,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of six directors to our board of directors, each to serve until the 2025 annual meeting of stockholders: Patrick Verheyen
CUE BIOPHARMA INC.’s own tally for this item (“Elect Director: Patrick Verheyen”): 13,138,525 for, 726,334 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following nominees to the Company's Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 31 asset managers below reported 2,428,070 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 61,732 | 0 | 0 | 0 | For |
| Dimensional | 56,839 | 0 | 0 | 0 | For |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,743 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 28,405 | 0 | 0 | 0 | For |
| Northern Trust | 16,002 | 0 | 0 | 0 | For |
| Voya | 13,439 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 11,159 | 0 | 0 | 0 | For |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 8,875 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 5,870 | 0 | 0 | 0 | For |
| Victory Capital | 5,748 | 0 | 0 | 0 | For |
| John Hancock | 5,565 | 0 | 0 | 0 | For |
| DWS | 5,402 | 0 | 0 | 0 | For |
| Jackson National | 5,401 | 0 | 0 | 0 | For |
| Principal | 4,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 4,042 | 0 | 0 | 0 | For |
| Calvert | 2,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
65% Majority: yes · of votes cast
Description as filed by funds: Election of six directors to our board of directors, each to serve until the 2025 annual meeting of stockholders: Peter A. Kiener
CUE BIOPHARMA INC.’s own tally for this item (“Elect Director: Peter A. Kiener”): 9,038,525 for, 4,822,811 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following nominees to the Company's Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:”
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 31 asset managers below reported 2,243,379 for, 184,691 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 61,732 | Withhold |
| Dimensional | 0 | 0 | 0 | 56,839 | Withhold |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,000 | 0 | 0 | 1,743 | Mixed |
| Managed Portfolio Series | 28,405 | 0 | 0 | 0 | For |
| Northern Trust | 16,002 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 13,439 | Withhold |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 11,159 | 0 | 0 | 0 | For |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 8,875 | Withhold |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 5,870 | Withhold |
| Victory Capital | 0 | 0 | 0 | 5,748 | Withhold |
| John Hancock | 0 | 0 | 0 | 5,565 | Withhold |
| DWS | 0 | 0 | 0 | 5,402 | Withhold |
| Jackson National | 0 | 0 | 0 | 5,401 | Withhold |
| Principal | 0 | 0 | 0 | 4,525 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 4,042 | Withhold |
| Calvert | 0 | 0 | 0 | 2,854 | Withhold |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
86% Approved · of votes cast
Description as filed by funds: The approval, on a non-binding advisory basis, of the compensation of our named executive officers.
CUE BIOPHARMA INC.’s own tally for this item (“3. A non-binding advisory proposal on the compensation of the Company's named executive officers, with votes cast”): 11,745,009 for, 1,924,707 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved a non-binding advisory proposal on the compensation of the Company's named executive officers, with votes cast as follows:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 61,732 | 0 | 0 | 0 | For |
| Dimensional | 0 | 56,839 | 0 | 0 | Against |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,000 | 1,743 | 0 | 0 | Mixed |
| Managed Portfolio Series | 0 | 28,405 | 0 | 0 | Against |
| Northern Trust | 16,002 | 0 | 0 | 0 | For |
| Voya | 13,439 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 11,159 | 0 | 0 | 0 | For |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 0 | 8,875 | 0 | 0 | Against |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 5,870 | 0 | 0 | 0 | For |
| Victory Capital | 5,748 | 0 | 0 | 0 | For |
| John Hancock | 5,565 | 0 | 0 | 0 | For |
| DWS | 5,402 | 0 | 0 | 0 | For |
| Jackson National | 0 | 5,401 | 0 | 0 | Against |
| Principal | 4,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 4,042 | 0 | 0 | 0 | For |
| Calvert | 0 | 2,854 | 0 | 0 | Against |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Fund voting reports, all 31 managers: 2,323,952 for, 104,118 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Bleichroeder LP | 2,744,586 | 0 | 0 | 0 | For |
| Slate Path Capital LP | 2,308,872 | 0 | 0 | 0 | For |
| BlackRock | 752,171 | 50 | 0 | 0 | For |
| State Street | 512,074 | 0 | 0 | 0 | For |
| Monaco Asset Management SAM | 0 | 326,204 | 0 | 0 | Against |
| ADVISORY RESEARCH INC | 257,225 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 0 | 238,800 | 0 | 0 | Against |
| Northern Trust | 211,662 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 148,000 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 141,493 | 0 | 0 | 0 | For |
| 1919 Investment Counsel, LLC | 131,720 | 0 | 0 | 0 | For |
| Baker Avenue Asset Management, LP | 0 | 93,320 | 0 | 0 | Against |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 77,000 | 0 | 0 | 0 | For |
| Citadel | 76,838 | 0 | 0 | 0 | For |
| Vanguard | 68,847 | 0 | 0 | 0 | For |
| Nuveen | 61,732 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 48,631 | 0 | 0 | 0 | For |
| Dimensional | 0 | 48,179 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 45,517 | 0 | 0 | 0 | For |
| Texas Capital Bank Wealth Management Services Inc | 35,437 | 0 | 0 | 0 | For |
| Goldman Sachs | 24,891 | 0 | 0 | 0 | For |
| Rhumbline | 16,843 | 0 | 0 | 0 | For |
| JPMorgan | 14,522 | 0 | 0 | 0 | For |
| Invesco | 0 | 14,042 | 0 | 0 | Against |
Institutional-manager reports, all 73 managers: 7,697,075 for, 921,798 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
CUE BIOPHARMA INC.’s own tally for this item (“2. The appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, with votes cast”): 32,418,349 for, 1,635,231 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, with votes cast as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 31 asset managers below reported 2,428,070 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,361,253 | 0 | 0 | 0 | For |
| BlackRock | 571,259 | 0 | 0 | 0 | For |
| Charles Schwab | 91,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,121 | 0 | 0 | 0 | For |
| TIAA | 61,732 | 0 | 0 | 0 | For |
| Dimensional | 56,839 | 0 | 0 | 0 | For |
| Fidelity | 36,055 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,743 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 28,405 | 0 | 0 | 0 | For |
| Northern Trust | 16,002 | 0 | 0 | 0 | For |
| Voya | 13,439 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 11,612 | 0 | 0 | 0 | For |
| Equitable | 11,159 | 0 | 0 | 0 | For |
| Pacific Life | 10,522 | 0 | 0 | 0 | For |
| American Century | 8,875 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 5,953 | 0 | 0 | 0 | For |
| ProShares | 5,870 | 0 | 0 | 0 | For |
| Victory Capital | 5,748 | 0 | 0 | 0 | For |
| John Hancock | 5,565 | 0 | 0 | 0 | For |
| DWS | 5,402 | 0 | 0 | 0 | For |
| Jackson National | 5,401 | 0 | 0 | 0 | For |
| Principal | 4,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 4,042 | 0 | 0 | 0 | For |
| Calvert | 2,854 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,354 | 0 | 0 | 0 | For |
Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 48,643,316 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.80% |
| 2 | BlackRock | 1.17% |
| 3 | Charles Schwab | 0.19% |
| 4 | QUANTITATIVE MASTER SERIES LLC | 0.13% |
| 5 | TIAA | 0.13% |
| 6 | Dimensional | 0.12% |
| 7 | Fidelity | 0.07% |
| 8 | Lincoln Financial | 0.07% |
| 9 | Managed Portfolio Series | 0.06% |
| 10 | Northern Trust | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Bleichroeder LP | 5.64% |
| 2 | Slate Path Capital LP | 4.75% |
| 3 | BlackRock | 1.55% |
| 4 | State Street | 1.05% |
| 5 | Monaco Asset Management SAM | 0.67% |
| 6 | ADVISORY RESEARCH INC | 0.53% |
| 7 | BANK OF AMERICA NA | 0.49% |
| 8 | Northern Trust | 0.44% |
| 9 | PNC BANK, NATIONAL ASSOCIATION | 0.30% |
| 10 | MELLON INVESTMENTS Corp | 0.29% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Bleichroeder LP | 12.60% | 13G |
| Vanguard Group | 6.25% | 13F |
| Mark E. Strome | 4.45% | 13G |
| Slate Path Capital LP | 1.89% | 13G |
| Geode Capital | 1.72% | 13F |
| State Street | 1.56% | 13F |
| BlackRock | 0.92% | 13F |
| Dimensional Fund Advisors | 0.89% | 13F |
| Northern Trust | 0.75% | 13F |
| Millennium Management | 0.74% | 13F |
Percentages above are of 48,643,316 shares outstanding, as reported by CUE BIOPHARMA INC. on its Form 10-Q dated May 6, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CUE BIOPHARMA INC.’s 10-Q dated May 6, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CUE BIOPHARMA INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “CUE BIOPHARMA (CUE) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cue-biopharma-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.